Abstract:In a cohort of patients with extensive‐stage small cell lung cancer undergoing immunotherapy, this study explored the role of radiotherapy and delve into brain metastases subgroup. Brain and thoracic radiotherapy were identified as favorable prognostic factors for survival in those with brain metastases. Moreover, prophylactic cranial irradiation and thoracic radiotherapy delayed intracranial progression in those initially without brain metastases. These findings underscore the pivotal role of local therapies in the management of extensive‐stage small cell lung cancer during the immunotherapy era. Background Extensive‐stage small cell lung cancer (ES‐SCLC) is a notoriously aggressive malignancy frequently associated with brain metastases (BMs), presenting substantial therapeutic challenges. This study delves into the effectiveness of immunotherapy combined with diverse radiotherapy, especially the influence of brain radiotherapy (BRT) on survival outcomes in the immunotherapy era. Methods ES‐SCLC patients treated at Xiangya Hospital and Xiangya Boai Hospital from February 2020 to June 2024 were retrospectively included. The study focused on patients receiving immune checkpoint inhibitors (ICIs). Metrics included overall survival (OS) and progression‐free survival (PFS), employing univariate and multivariate Cox regression models for statistical analysis. Results A total of 393 patients with ES‐SCLC who received ICIs were included in the study. Within the entire cohort, the presence of baseline BMs did not statistically affect OS or PFS. However, thoracic radiotherapy (TRT) was identified as a favorable prognostic factor for both OS and PFS. BRT demonstrated a beneficial effect on OS across both the general cohort and the baseline_BMs subgroup. In patients from the baseline_BMs subgroup who had previously undergone TRT, ICIs plus BRT did not significantly improve OS compared to ICIs alone. Conversely, for patients who had not received prior TRT, adding BRT to ICIs significantly enhanced OS. Among the patients who underwent BRT, 71 received whole brain radiotherapy (WBRT) while 19 opted for stereotactic radiosurgery (SRS). No significant differences in OS and PFS were observed between the SRS and WBRT modalities. The sequence of ICIs relative to BRT was found to influence PFS adversely. Administering BRT before ICIs (RT‐ICI) was associated with worse PFS compared to administering ICIs followed by BRT (ICI‐RT). Additionally, no significant differences in OS and PFS were noted among the three subgroups defined by varying intervals between ICIs and BRT. For patients without baseline BMs, TRT and prophylactic cranial irradiation were associated with delayed onset of brain metastases. Conclusions Our study underscores the importance of optimizing treatment strategies and considering the timing and integration of radiotherapy and immunotherapy to improve outcomes for patients with ES‐SCLC, particularly those at risk of or presenting with BMs.

Clinical outcomes and timing on the combination of focal radiation therapy and immunotherapy for the treatment of brain metastases

1439P Brain Radiotherapy Combined with Camrelizumab and Platinum-Based Chemotherapy As First-Line Treatment for Advanced NSCLC with Brain Metastases: A Multicenter, Open-Label, Single-Arm, Phase II Study

Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases

Combination of radiosurgery and immunotherapy in brain metastases: balance between efficacy and toxicities

Optimizing the synergy between stereotactic radiosurgery and immunotherapy for brain metastases

Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic

Radiotherapy plus EGFR TKIs in non‐small cell lung cancer patients with brain metastases: an update meta‐analysis

Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review

Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis

Local Control Outcomes for Combination of Stereotactic Radiosurgery and Immunotherapy for Non-Small Cell Lung Cancer Brain Metastases

The Safety and Efficacy of Concurrent Immune Checkpoint Blockade and Stereotactic Radiosurgery Therapy with Practitioner and Researcher Recommendations

Synergistic effects of radiotherapy and targeted immunotherapy in improving tumor treatment efficacy: a review

Radiation therapy and immunotherapy: what is the optimal timing or sequencing?

Efficacy of Different Therapies for Brain Metastases of Non-Small Cell Lung Cancer: a Systematic Review and Meta-Analysis

Current status and perspectives of interventional clinical trials for brain metastases: analysis of ClinicalTrials.gov

EPID-01. ANTINEOPLASTIC, RADIATION, AND SYNCHRONICITY EFFECTS ON BRAIN METASTASIS SURVIVAL: A RETROSPECTIVE POPULATION-BASED STUDY

Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review

TRSC-07 COMBINATION OF ENDOCRINE THERAPY WITH RADIATION DECREASES BRAIN METASTASES THROUGH REACTIVATION OF EFFECTOR IMMUNE-CELL RECRUITMENT TO THE BRAIN

Treatment of melanoma brain metastases with radiation and immunotherapy or targeted therapy: A systematic review with meta-analysis

The Optimal Radiotherapy Strategy for Patients With Small Cell Lung Cancer and Brain Metastasis: A Retrospective Analysis

Stereotactic Radiosurgery Combined with Targeted Therapy for Brain Metastasis: A Systematic Review and Meta-Analysis